Tanya Siddiqi, M.D.

(877) 460-4673
Tanya Siddiqi, M.D.
Hematologist
Clinical Expertise
  • Chronic Lymphocytic Leukemia
  • Hematopoietic Cell Transplantation
  • B Cell Non-Hodgkin Lymphoma (B-NHL)
Research Area
  • Chronic Lymphocytic Leukemia
  • Cellular Therapy in Lymphoma
Academic Appointments
  • Medical Director of Lymphoma and ILL Programs, City of Hope Orange County
  • Director, Chronic Lymphocytic Leukemia Program, Toni Stephenson Lymphoma Center
  • Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Lymphoma
Immunotherapy
Tanya Siddiqi, M.D., is an accomplished hematologist-oncologist who specializes in diagnosing and treating blood cancers, particularly chronic lymphocytic leukemia (CLL) and B cell non-Hodgkin lymphoma (B-NHL).
 
In addition to her clinical practice, Dr. Siddiqi is also principal investigator on a number of clinical trials evaluating the role of targeted therapies, including gene therapy (CAR T cell therapy) and other novel agents primarily in diseases like CLL and B-NHL.
 
Dr. Siddiqi earned her medical degree at Aga Khan University Medical College in Karachi, Pakistan. Afterward, she completed an internal medicine residency at University of Connecticut Health Center, followed by fellowships in hematology/oncology at Beth Israel Deaconess Medical Center (Harvard Medical School, Boston) and hematopoietic stem cell transplantation at City of Hope.
 
Dr. Siddiqi is a member of the Toni Stephenson Lymphoma Center and the Immunotherapy Disease Team.

Location

Education & Experience

Degrees

  • 2000, M.B.B.S., Aga Khan University Medical College, Karachi, Pakistan

Fellowship

  • 2009-2010, Hematopoietic Cell Transplantation, City of Hope, Duarte, California
  • 2006-2009, Hmatology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts

Residency

  • 2003-2006, Internal Medicine, University of Connecticut Health Center, Farmington, Connecticut

Professional Experience

  • 2025-present, Medical Director of the ILL Program, City of Hope Orange County
  • 2022-present, Medical Director of Lymphoma, City of Hope, Orange County, CA
  • 2019-present, Director, Chronic Lymphocytic Leukemia Program, Toni Stephenson Lymphoma Center, City of Hope
  • 2024-present, Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California
  • 2018-2024, Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California

Awards & Memberships

Awards

  • 2016, Best Lymphoma Abstract Award, Lymphoma and Myeloma, New York, New York, October 13-15, 2016

  • 2016, Pasadena Magazine Top Doctor, August 2016

  • 2012, Phase 1 Program Correlative Science Award, City of Hope

  • 2009, Tim Nesvig Lymphoma Foundation Grant

  • 2008, American Association for Cancer Research Molecular Biology in Clinical Oncology Workshop Award

Memberships

  • American Society of Blood and Marrow Transplantation

  • American Society of Clinical Oncology

  • American Society of Hematology

  • Member, National Comprehensive Cancer Network, CLL/NHL Panel

Publications

  • Xiao A, Chen L, Pak S, Lee B, Mei M, Budde E, Siddiqi T, Godfrey J, Herrera A, Kallam A, Phillips T, Baird JH, Borogovac A, Kwak L, Rosen ST, Danilov A, Dadwal S, Shouse G, Thiruvengadam SK. Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphoma. Leuk Lymphoma. 2025 Aug 5:1-9. doi: 10.1080/10428194.2025.2540442. Epub ahead of print. PMID: 40765130.
  • Castillo JJ, Guijosa A, Allan JN, Siddiqi T, Advani RH, Flynn C, Meid KE, Budano N, Nguyen J, Ramirez-Gamero A, Tsakmaklis N, Hunter ZR, Patterson CJ, Treon SP, Sarosiek S. Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia. Blood Adv. 2025 Jul 17:bloodadvances.2025016890. doi: 10.1182/bloodadvances.2025016890. Epub ahead of print. PMID: 40674749.
  • Shouse G, Chen C, Muir A, Popplewell L, Siddiqi T, Zain J, Herrera AF, Danilova O, Roleder C, Wang L, Spurgeon SEF, Kittai AS, Chen L, Xia Z, Davids MS, Danilov AV. Safety and efficacy of the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trial. Haematologica. 2025 Jul 3. doi: 10.3324/haematol.2024.286945. Epub ahead of print. PMID: 40605718.
  • Kharfan-Dabaja MA, Kumar A, Pinilla-Ibarz J, Brown JR, Shadman M, Awan FT, Kenderian SS, Siddiqi T, Abramson JS, Al-Juhaishi T, Brander DM, Coombs CC, Furman RR, Jain N, Khan N, Saba NS, Collins JM, Beitinjaneh A, Stephens DM, Woyach J, Hamadani M. Clinical practice recommendations on the role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy in patients with chronic lymphocytic leukemia on behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2025 Jun 11:S2666-6367(25)01219-9. doi: 10.1016/j.jtct.2025.06.002. Epub ahead of print. PMID: 40514010.
  • Kittai AS, Marchetti M, Al-Sawaf O, Benjamini O, Danilov AV, Davids MS, Eichhorst BF, Eyre TA, Frustaci AM, Hallek MJ, Hampel PJ, Herishanu Y, Hicks RJ, Kater AP, King RL, Martín-Subero JI, Owen C, Parry EM, Ponzoni M, Rossi D, Siddiqi T, Stilgenbauer S, Tam CS, Ten Hacken E, Thompson PA, Wierda WG, Gaidano G, Woyach JA, Ghia P. International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: the ERIC Recommendations. Blood. 2025 Apr 16:blood.2024028064. doi: 10.1182/blood.2024028064. Epub ahead of print. PMID: 40239121.
  • Locke FL, Siddiqi T, Jacobson CA, Nikiforow S, Ahmed S, Miklos DB, Lin Y, Lunning MA, Hill BT, Ghobadi A, Hu ZH, Hemmer MT, Zoratti MJ, Vunnum S, Tsang J, Spooner C, Smith H, Fu C, Patel A, Miao H, Shahani SA, Mirjah DL, Xu H, Pasquini MC. Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel. Blood Adv. 2025 Jun 10;9(11):2663-2676. doi: 10.1182/bloodadvances.2024013656. PMID: 39883946; PMCID: PMC12155625.
  • Woo JS, Nguyen K, Liu L, Krishnan A, Siddiqi T, Borogovac A. Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy. Semin Hematol. 2024 Oct;61(5):273-283. doi: 10.1053/j.seminhematol.2024.08.003. Epub 2024 Aug 22. PMID: 39327109.
  • Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Kersten MJ, Zheng Y, Zhang T, Nater J, Shen R, Miao H, Kim JJ, Miklos DB. Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma. Transplant Cell Ther. 2024 Nov;30(11):1065-1079. doi: 10.1016/j.jtct.2024.08.018. Epub 2024 Aug 24. PMID: 39187161.
  • Siddiqi T. CARs vs bispecifics: the race is on! Blood. 2024 Aug 8;144(6):592-593. doi: 10.1182/blood.2024025130. PMID: 39115828.
  • Lyer P, Zhang B, Liu T, Jin M, Hart K, Zhang J, Siegert V, Remke M, Wang X, Yu L, Song J, Venkataraman G, Chan WC, Jia Z, Buchner M, Siddiqi T, Rosen ST, Danilov A, Wang L. MGA deletion leads to Richter's transformation by modulating mitochondrial OXPHOS. Sci Transl Med. 2024 Jul 31;16(758):eadg7915. doi: 10.1126/scitranslmed.adg7915. Epub 2024 Jul 31. PMID: 39083585.

Chapters:

  • Siddiqi T. Chronic lymphocytic leukemia: Biology and Treatment. Siddiqi T. (2021) Chronic Lymphocytic Leukemia (CLL): Biology and Therapy. In: Pullarkat V., Marcucci G. (eds) Biology and Treatment of Leukemia and Bone Marrow Neoplasms. Cancer Treatment and Research, vol 181. Springer, Cham. https://doi.org/10.1007/978-3-030-78311-2_8

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
4.9
Recommend this provider office
4.9
Provider explain in way you understand
4.9
Provider listen carefully to you
4.9
Know important info medical history
4.9
Show respect for what you say
4.9
Spend enough time with you
4.9
Rate provider 0-10
08/27/26
My care provider was terrific. - Verified patient
08/17/26
Dr Siddiqi is the best lymphoma specialist. We trust her very much. - Verified patient
08/10/26
Dr Siddiqi is not only a world class physician but a compassionate professional.....IMO, she sets the gold standard of medical care - Verified patient
07/01/26
I did feel a bit dismissed as though my input was not important because I am "not a physician" which was said twice. [...] - Verified patient
06/13/26
She is the best, period! - Verified patient